LIVE ATTENUATED BACTERIAL VACCINES AGAINST ANTHRAX

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$120,511.00
Award Year:
2002
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI053021-01
Award Id:
60594
Agency Tracking Number:
AI053021
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
AVANT IMMUNOTHERAPEUTICS, INC., 119 4TH AVE, NEEDHAM, MA, 02494
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
SIMS KOCHI
(781) 433-3161
SKOCHI@AVANTIMMUNE.COM
Business Contact:
UNA RYAN
(781) 433-0771
URYAN@AVANTIMMUNE.COM
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): The ability to prepare anthrax spores inexpensively and deliver them in an aerosol form, and the high mortality rate of inhalation anthrax, has made Bacillus anthracis one of the most feared agents of biological warfare and terrorism. Despite recent advances in understanding anthrax, no sustained effort has been made to develop new prophylactic or therapeutic agents to protect or treat against the disease. The current anthrax vaccine (AVA) consists of an alum-adsorbed culture filtrate, principally containing the anthrax toxin protective antigen (PA), from an attenuated strain of B. anthracis. Immunization with AVA requires multiple doses over 18 months and occasionally produces local reactogenicity in vaccinees. Accordingly, there is a critical requirement for an improved anthrax vaccine. The delivery of foreign antigens using live vectors is well suited for vaccines against diseases in which a rapid immune response against an antigen(s) is important for protection. The goal of this proposal is to evaluate the potential of live, attenuated strains of Vibrio cholerae and Salmonella typhimurium expressing PA, as improved anthrax vaccines. The Specific Aims of this project are to (1) construct attenuated V. cholerae and S. typhimurium vectors expressing recombinant PA, (2) evaluate the colonization and immunogenicity of (1) in pre-clinical models, and (3) evaluate the efficacy of (1) using anthrax toxin challenge in appropriate animal models. The successful accomplishment of these aims will provide new anthrax vaccines with the potential to confer protective immunity by oral immunization in humans.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government